Elizabeth Ortiz, M.D., a Texas-based rheumatologist and clinical adviser at WellTheory, a platform specializing in autoimmune disease treatment
Retatrutide is designed to activate these three receptors in a way that affects appetite, fullness, glucose control and metabolism
Oral Semaglutide (Wegovy Pill) - FDA Approved December 2025: According to the OASIS 4 trial published in the New England Journal of Medicine, participants who took the Wegovy pill experienced 13.6% mean weight loss over approximately 64 weeks when including all participants regardless of adherence, compared to 2.2% for those taking placebo
Promotes gastric health and comfort
I did not look deflated or saggy the way I was worried about
Yet most published protocols overlook the temporal coordination required to capture both compounds at peak efficacy